A Jennifer Doudna‑linked spinout, Azalea Therapeutics, closed a notable funding round — reported at $82 million total — to pursue in vivo CAR‑T approaches designed to convert patients’ immune cells into therapeutic effectors with a single administration. The company described a dual‑vector strategy intended to enable permanent gene modification in situ and accelerate access to CAR‑T modalities without ex vivo manufacturing. Investors view in vivo CAR‑T as a high‑risk, high‑reward pathway to broaden cell therapy access and reduce logistics costs. Azalea’s raise follows other high‑profile in vivo gene efforts and could catalyze competition over delivery vectors, safety switches, and regulatory pathways for single‑dose cell‑reprogramming therapeutics. Translational benchmarks will include on‑target editing, off‑target profiling, and durable safety signals in early human studies.